|
|
|
| Efficacy of Recombinant Human Thrombopoietin Combined with Rituximab in the Treatment of Immune Thrombocytopenia and Its Influence on Coagulation Function and Adverse Reactions |
| LIU Dan, FU Xiangjun, CHEN Wenting, et al |
| Hainan General Hospital / Hainan Hospital Affiliated to Hainan Medical College, Hainan Haikou 570311, China |
|
|
|
|
Abstract Objective: To explore the efficacy of recombinant human thrombopoietin (rhTPO) combined with rituximab in the treatment of immune thrombocytopenia (ITP) and its influence on coagulation function and adverse reactions. Methods: A total of 198 patients with ITP in our hospital were retrospectively analyzed, and they were grouped according to the treatment regimens. Propensity score matching was conducted according to the general data of patients, and finally 61 cases in control group and 63 cases in study group with balanced general data were obtained. Control group was treated with rituximab, and observation group was treated with rhTPO combined with rituximab. The clinical efficacy, platelet count (PLT), coagulation function and adverse reactions were compared between the two groups. Results: After treatment, the clinical total effective rate was 68.85% in study group and 80.95% in control group (P>0.05), but the complete response rate of patients in study group was significantly higher than that in control group (P<0.05), and the onset time was significantly shorter than that in control group (P<0.05). The PLT levels after 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment in the two groups were all higher than those before treatment (P<0.05), and the PLT levels in study group after 2 weeks, 4 weeks, 8 weeks and 12 weeks of treatment were higher than those in control group (P<0.05). Before and after treatment, there were no significant differences in the levels of activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen (FIB) between the two groups (P>0.05), and there were no statistically significant differences in the levels of indicators between the groups (P>0.05). During treatment, there was no significant difference in the incidence rate of adverse reactions between control group and observation group (19.67% vs 25.40%) (P>0.05). Conclusion: RhTPO combined with rituximab has a significant efficacy in the treatment of ITP. It can increase the level of PLT in a short period of time, and it does not adversely affect the coagulation function, with clinical safety of medication.
|
|
|
|
|
|
[1] 甘加宽,陈飞宇,樊憬懿,等.原发免疫性血小板减少症动物模型研究进展[J].中国实验方剂学杂志,2017,23(3):200~206.
[2] 袁永平,杨翔,陈懿建.原发性免疫性血小板减少症的发病机制研究进展[J].中国实验血液学杂志,2019,27(5):1706~1710.
[3] 杨仁池.难治性原发免疫性血小板减少症定义及临床处理[J].中国实用内科杂志,2017,37(2):96~98.
[4] Arai Y,Jo T,Matsui H,et al.Comparison of up-front treatments for newly diagnosed immune thrombocytopenia-a systematic review and network meta-analysis[J].Haematologica,2018,103(1):163~171.
[5] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2):89~93.
[6] Lambert MP,Gernsheimer TB.Clinical updates in adult immune thrombocytopenia[J].Blood,2017,129(21):2829~2835.
[7] 李姜惠子,刘洋,王秀娟,等.sPD-1/sPD-L1与Th1/Th2及Th17/Treg相关细胞因子在原发免疫性血小板减少症中的研究[J].中国免疫学杂志,2019,35(4):467~470.
[8] Hung C,Tzung-Chih T,Yu-Shin H,et al.Immune thrombocytopenia: effectiveness of frontline steroids and comparison of azathioprine,splenectomy,and rituximab as second-line treatment[J].Eur Haematol.2018; 101: 549~555.
[9] 聂牧,倪晓菲,秦平,等.单次利妥昔单抗治疗原发免疫性血小板减少症的疗效及安全性[J].山东大学学报(医学版),2018,56(5):81~84.
[10] 姜明敏,李玉婷,王丽娟,等.血小板生成素对免疫性血小板减少小鼠脾脏T淋巴细胞亚群的影响[J].免疫学杂志,2019,35(8):671~676.
[11] 周海,彭军,侯明.利妥昔单抗联合重组人血小板生成素对比利妥昔单抗治疗糖皮质激素无效或复发免疫性血小板减少症的多中心、前瞻性、随机对照临床研究[J].中华内科杂志,2016,55(2):153.
[12] 冨山,佳昭.Recent advance in ITP management : efficacy and safety of TPO receptor agonists and rituximab[J].Hematology,2018,77(1):54~60. |
|
|
|
2021, Vol. 27 
